These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21127708)

  • 21. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population.
    Borgiani P; Ciccacci C; Forte V; Sirianni E; Novelli L; Bramanti P; Novelli G
    Pharmacogenomics; 2009 Feb; 10(2):261-6. PubMed ID: 19207028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic epidemiology of pharmacogenetic variations in CYP2C9, CYP4F2 and VKORC1 genes associated with warfarin dosage in the Indian population.
    Giri AK; Khan NM; Grover S; Kaur I; Basu A; Tandon N; Scaria V; ; ; Kukreti R; Brahmachari SK; Bharadwaj D
    Pharmacogenomics; 2014 Jul; 15(10):1337-54. PubMed ID: 25155935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of CYP2C9, CYP4F2 and VKORC1 genetic polymorphisms on pharmacokinetics and pharmacodynamics of mean daily maintenance dose of warfarin in Chinese patients.
    Zhuang W; Wen W; Xuan B; Chen Y; Cao Y; Sun Z; Ma J
    Blood Coagul Fibrinolysis; 2015 Mar; 26(2):167-74. PubMed ID: 25304014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients.
    Wattanachai N; Kaewmoongkun S; Pussadhamma B; Makarawate P; Wongvipaporn C; Kiatchoosakun S; Vannaprasaht S; Tassaneeyakul W
    Eur J Clin Pharmacol; 2017 Aug; 73(8):973-980. PubMed ID: 28550460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Impact of six genetic polymorphisms on Warfarin maintenance dose variation in Chinese Han population].
    Lou Y; Han L; Li Y; Zhang X; Liu Z; Tang M; Yu H; Wang W; Xu J; Liu H; Li Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2014 Jun; 31(3):367-71. PubMed ID: 24928022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction.
    Carlquist JF; Horne BD; Mower C; Park J; Huntinghouse J; McKinney JT; Muhlestein JB; Anderson JL
    J Thromb Thrombolysis; 2010 Oct; 30(3):358-64. PubMed ID: 20499136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients.
    Wakamiya T; Hokosaki T; Tsujimoto S; Kadota K; Nakano Y; Watanabe S; Iwamoto M; Yanagimachi M; Ito S
    Mol Diagn Ther; 2016 Aug; 20(4):393-400. PubMed ID: 27262824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic polymorphisms of VKORC1, CYP2C9, CYP4F2 in Bai, Tibetan Chinese.
    Zeng WT; Zheng QS; Huang M; Cen HJ; Lai Y; Chen WY; Zhao LZ; Leng XY
    Pharmazie; 2012 Jan; 67(1):69-73. PubMed ID: 22393834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis.
    Takeuchi M; Kobayashi T; Biss T; Kamali F; Vear SI; Ho RH; Bajolle F; Loriot MA; Shaw K; Carleton BC; Hamberg AK; Wadelius M; Hirono K; Taguchi M; Wakamiya T; Yanagimachi M; Hirai K; Itoh K; Brandão LR; Ito S
    Pharmacogenomics J; 2020 Apr; 20(2):306-319. PubMed ID: 31673144
    [TBL] [Abstract][Full Text] [Related]  

  • 30. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children.
    Biss TT; Avery PJ; Brandão LR; Chalmers EA; Williams MD; Grainger JD; Leathart JB; Hanley JP; Daly AK; Kamali F
    Blood; 2012 Jan; 119(3):868-73. PubMed ID: 22010099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Influence of warfarin related genes and non- genetic factors on administrative dose in Shanghai area].
    Zhuang W; Wu D; Wang Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):13-7. PubMed ID: 24602724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of VKORC1, CYP4F2 and NQO1 gene variants on warfarin dose requirement in Han Chinese patients with catheter ablation for atrial fibrillation.
    Li J; Yang W; Xie Z; Yu K; Chen Y; Cui K
    BMC Cardiovasc Disord; 2018 May; 18(1):96. PubMed ID: 29776386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU.
    Scott SA; Patel M; Martis S; Lubitz SA; van der Zee S; Yoo C; Edelmann L; Halperin JL; Desnick RJ
    Pharmacogenomics; 2012 Feb; 13(3):297-307. PubMed ID: 22188360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients.
    Pautas E; Moreau C; Gouin-Thibault I; Golmard JL; Mahé I; Legendre C; Taillandier-Hériche E; Durand-Gasselin B; Houllier AM; Verrier P; Beaune P; Loriot MA; Siguret V
    Clin Pharmacol Ther; 2010 Jan; 87(1):57-64. PubMed ID: 19794411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study.
    Zambon CF; Pengo V; Padrini R; Basso D; Schiavon S; Fogar P; Nisi A; Frigo AC; Moz S; Pelloso M; Plebani M
    Pharmacogenomics; 2011 Jan; 12(1):15-25. PubMed ID: 21174619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese.
    Cha PC; Mushiroda T; Takahashi A; Kubo M; Minami S; Kamatani N; Nakamura Y
    Hum Mol Genet; 2010 Dec; 19(23):4735-44. PubMed ID: 20833655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms.
    Wypasek E; Branicka A; Awsiuk M; Sadowski J; Undas A
    Thromb Res; 2014 Sep; 134(3):604-9. PubMed ID: 25042728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of CYP4F2 polymorphisms and plasma vitamin K levels on warfarin sensitivity in Japanese pediatric patients.
    Hirai K; Hayashi H; Ono Y; Izumiya K; Tanaka M; Suzuki T; Sakamoto T; Itoh K
    Drug Metab Pharmacokinet; 2013; 28(2):132-7. PubMed ID: 22892446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy.
    Hirai K; Yamada Y; Hayashi H; Tanaka M; Izumiya K; Suzuki M; Yoshizawa M; Moriwaki H; Akimoto T; Tsuji D; Inoue K; Itoh K
    Thromb Res; 2015 May; 135(5):861-6. PubMed ID: 25747538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.